Radiopharm Theranostics (ASX: RAD) announced the publication of a significant clinical study featuring 68Ga-Trivehexin. Dr. Rehm and colleagues from the esteemed Technische Universität Dresden led this groundbreaking research, which has now been published in Frontiers in Nuclear Medicine. With a cohort of 44 individuals, this study represents the largest group ever imaged with RAD 301 and any tracer, underscoring its importance in the field.
The findings reveal remarkable imaging capabilities, showcasing a high tumor-to-background ratio that facilitates the visualization of the primary tumor and metastases across critical areas—including the liver, lymph nodes, peritoneum, lung, bone, spleen, pleural cavity, and soft tissues. Most notably, with no adverse events reported, this evidence solidifies RAD 301 as a safe and effective diagnostic agent for imaging αvβ6-integrin expression in pancreatic cancer, promising a brighter future for needy patients.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
